Effect of solid state transition on the physical stability of suspensions containing bupivacaine lipid microparticles.
Bupivacaine lipid microparticles were prepared and evaluated as a parenteral sustained-release dosage form for postoperative pain management. Bupivacaine free base was incorporated into a molten tristearin matrix and lipid micro-particles were subsequently formed from this molten mixture by a spray-congealing process. A 3% injectable bupivacaine lipid microparticle suspension was prepared by dispersing 30% bupivacaine lipid microparticles in an aqueous medium containing carboxymethylcellulose (CMC), mannitol, and Tween 80. Upon room temperature storage, the fluid suspension gradually changed into a nonflowing semisolid (gelation) as a result of crystal growth of bupivacaine. However, suspensions prepared with bupivacaine lipid microparticles that were previously annealed at an elevated temperature remained fluid upon long-term storage. Differential scanning calorimetry (DSC), x-ray powder diffraction (XRPD), and isoperibol solution calorimetry were used to investigate the changes in the solid-state properties of tristearin and bupivacaine in the lipid microparticles before and after the heat treatment. The DSC and XRPD results indicate that after 24 hours of heating at 40 degrees C, tristearin was completely converted from the unstable alpha form to the stable beta form. Using the isoperibol solution calorimetric method, bupivacaine was found to transform into a more stable form after the lipid microparticles were heated at 60 degrees C for 24 hours. The generation of the unstable solid forms of tristearin and bupivacaine was attributed to the resolidification of both components from the molten mixture during the spray-congealing process.
Li
Luk Chiu
LC
Global Parenteral Development and Advanced Drug Delivery, Global Pharmaceutical Research and Development Division, Abbott Laboratories, 100 Abbot Park Rd., Bldg. AP4, Dept. R43D, Abbott Park, IL 60064-6075, USA. Lukchiu.li@abbott.com
Zhu
Lihua
L
Song
Jing-Feng
JF
Deng
Jone-Shin
JS
Bandopadhyay
Rubi
R
Wurster
Dale E
DE
D000779:Anesthetics, Local / Q000008:administration & dosage* / Q000737:chemistry; D002045:Bupivacaine / Q000008:administration & dosage* / Q000737:chemistry; D002152:Calorimetry, Differential Scanning; D055598:Chemical Phenomena; D002627:Chemistry, Physical; D004355:Drug Stability; D005079:Excipients; D008055:Lipids; D008855:Microscopy, Electron, Scanning; D008863:Microspheres; D010316:Particle Size; D013535:Suspensions; D014280:Triglycerides / Q000737:chemistry; D014961:X-Ray Diffraction
D000779:Anesthetics, Local; D005079:Excipients; D008055:Lipids; D013535:Suspensions; D014280:Triglycerides; C022618:tristearin; D002045:Bupivacaine